Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

There’s a war brewing over blockbuster weight loss medications — and patients ... Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name ...

Novo and Lilly are also working on oral weight loss drugs ... has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to ...

The Eli Lilly deal includes a "real-world" study into how its weight-loss drugs impact "participants' employment status and sick days," among other factors. LONDON — U.S. pharmaceutical giant ...